First time in Human Study of AZD8701 with or without Durvalumab in Participants with Advanced Solid Tumours

Trial Identifier: D9950C00001
Sponsor: AstraZeneca
NCTID:: NCT04504669
Start Date: August 2020
Primary Completion Date: January 2025
Study Completion Date: January 2025
Condition: Cancer - Other; Esophageal cancer; Skin Cancer; Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CA, AB Edmonton, AB, CA, T6G 1Z2
CA, ON Toronto, ON, CA, M5G 2M9
ES Barcelona, ES, 08035
ES L'Hospitalet de Llobregat, ES, 08907
ES Madrid, ES, 28007
ES Madrid, ES, 28050
ES Madrid, ES, 28027
ES Madrid, ES, 28041
FR Creteil, FR, 94010
FR Rennes, FR, 35000
FR Toulouse Cedex 09, FR, 31059
FR Villejuif Cedex, FR, 94805
US, CA La Jolla, CA, US, 92093
US, KY Lexington, KY, US, 40536
US, MD Baltimore, MD, US, 21287
US, MO Saint Louis, MO, US, 63110
US, NC Huntersville, NC, US, 28078
US, NJ New Brunswick, NJ, US, 08901
US, TN Franklin, TN, US, 37067
US, TX Houston, TX, US, 77030
US, VA Arlington, VA, US, 22205
US, WA Seattle, WA, US, 98109
US, WI Madison, WI, US, 53792